Premium
Non‐cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience
Author(s) -
Ramzi Mani,
Zakerinia Maryam,
Nourani Habib,
Dehghani Mehdi,
Vojdani Reza,
Haghighinejad Hourvash
Publication year - 2011
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2011.01432.x
Subject(s) - medicine , multiple myeloma , melphalan , transplantation , surgery , hematopoietic stem cell transplantation , single center , autologous stem cell transplantation , apheresis , regimen , cryopreservation , stem cell , platelet , embryo , genetics , biology , microbiology and biotechnology
Ramzi M, Zakerinia M, Nourani H, Dehghani M, Vojdani R, Haghighinejad H. Non‐cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience.
Clin Transplant 2012: 26: 117–122.
© 2011 John Wiley & Sons A/S. Abstract: Several clinical trials have shown the superiority of high‐dose therapy (HDT) and autologous stem cell transplantation (ASCT) over conventional dose therapy for patients with multiple myeloma. There is limited experience with non‐cryopreserved autologous hematopoietic stem cell transplantation. Between January 2004 and February 2010, we treated 38 patients with myeloma (mean age = 50.6) with a preparative regimen of Melphalan 140–200 mg/m 2 and non‐cryopreserved ASCT. All the apheresis products were kept in a conventional blood bank refrigerator at 4°C for 2 d before infusion. The median time to platelet count of >20 × 10 9 /L was 13 d (range 10–31). Also, the median time to absolute neutrophil count >0.5 × 10 9 /L was 11 d (range 9–21). All the 38 patients were engrafted and there was not graft failure in this study group. Twenty‐nine of 38 (76.3%) patients are alive and without disease activity after a median follow‐up of 31 months (range 6–77). Responses (complete and partial response) were seen in all the 38 patients. The median progression‐free survival was 27 months with 95% confidence interval 23.52–30.48, whereas the median overall survival was 30 months. One hundred days transplant‐related mortality was 0%. HDT and autologous transplantation without cryopreservation is an effective and safe method which simplifies the procedure and is feasible and cost saving in our patients.